Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
نویسندگان
چکیده
Omalizumab (OMA), a humanized anti-immunoglobulin E (IgE) monoclonal antibody was approved in the EU in 2005 as an add-on therapy for patients with severe persistent allergic asthma (AA). We present an overview of recent developments in the use of OMA for this indication. Approval for pediatric use: followed the completion of two clinical trials in children 6 to <12 years of age with moderate-to-severe AA, who were either wellor inadequately controlled with inhaled corticosteroids (CS). Pooled analysis of these data demonstrated the efficacy and safety of OMA and led to approval in the EU for use in this population.
منابع مشابه
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma. Omalizumab, an anti-IgE monoclonal antibody, binds to the FcɛRI binding site on free IgE. As a result, circulating free IgE is reduced, IgE is prevented from attaching to mast cells and basophils, and FcɛRI receptor expression is down-regulated. The inflammatory response to allergens and the acute and chronic effector ...
متن کاملTargeted therapy in severe asthma today: focus on immunoglobulin E
Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes,...
متن کاملRecent Progress in Allergen Immunotherapy
The efficacy of allergen immunotherapy for the treatment of allergic rhinoconjunctivitis with or without seasonal bronchial asthma and anaphylaxis caused by the sting of the hymenoptera class of insects has been clearly demonstrated in numerous well-designed, placebo-controlled trials. Immunotherapy whether by subcutaneous injection of allergen extract or by oral/sublingual routes modifies peri...
متن کاملTreating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
Increased asthma severity is not only associated with enhanced recurrent hospitalisation and mortality but also with higher social costs. Most cases of asthma are atopic in nature, with the trigger for acute asthma attacks and chronic worsening of inflammation being allergens inducing an immune response through immunoglobulins of IgE class. Currently antiinflammatory treatments are effective fo...
متن کاملOmalizumab: Clinical Use for the Management of Asthma
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β(2) agonist bronchodilators. This review considers the mechanism of action, pharmacokinetics, efficacy, safety and place in management of omalizumab in a...
متن کامل